ELTX

Elicio Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-12

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.56USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
8.87Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.32 against 0.71 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

1.13x

1.57x

1.51x

0.23x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Salesn/a
Its own average over 7 years, 7.6M.
Profit1.13x
Its own average over 10 years, -34.9M.
Free cash flow1.57x
Its own average over 10 years, -23.6M.
Debt1.51x
Its own average over 9 years, 9.6M.
Price0.23x
Its own average over 4 years, 7. Market data, 2026-11-04

Price is furthest from its own average, at 0.23 times.

Profit is 1.13 times its own 10-year average; Free cash flow is 1.57 times its own 10-year average; Debt is 1.51 times its own 9-year average; Price is 0.23 times its own 4-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales against its own 7-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Profit against its own 10-year average1.13
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.57
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Debt against its own 9-year average1.51
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Price against its own 4-year average0.23Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD